Previous 10 | Next 10 |
The following slide deck was published by Alkermes plc in conjunction with their 2021 Q4 earnings call. For further details see: Alkermes plc 2021 Q4 - Results - Earnings Call Presentation
Alkermes press release (NASDAQ:ALKS): Q4 Non-GAAP EPS of $0.23 beats by $0.10. Revenue of $324.5M (+15.9% Y/Y) beats by $17.95M. Shares -0.51% PM. For further details see: Alkermes Non-GAAP EPS of $0.23 beats by $0.10, revenue of $324.5M beats by $17.95M
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022 -- Revenues of $1.17 Billion in 2021, GAAP Loss per Share of $0.30 and Diluted Non-GAAP Earnings per Share of $0.78 -- -- Financial Expecta...
Alkermes (NASDAQ:ALKS) is scheduled to announce Q4 earnings results on Wednesday, Feb. 16, before market open. The consensus EPS estimate is $0.17 (+70% Y/Y) and the consensus revenue estimate is $308.69M (+10.2% Y/Y). Over the last 2 years, ALKS has beaten EPS estimates 100% of the time and ...
--News Direct-- Did you know that that there is a type of melanoma that is not visible on skin? Watch this video to learn about mucosal melanoma including treatment challenges, and unmet needs. About Alkermes Alkermes plc is a fully-integrated, global biopharmaceutical comp...
Alkermes (NASDAQ:ALKS) is trading ~6% higher on Monday after the company announced topline results from its ENLIGHTEN-Early trial suggesting the Phase 3 study for the schizophrenia therapy LYBALVI met the main goal with a statistically significantly less weight gain among patients. ...
Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness - LYBALVI Demonstrated Less Weight Gain Compared to Olanzapine in Patients With Schizophrenia, Schizophreniform Disorder or Bipolar I Disorder - PR N...
Alkermes to Report Fourth Quarter and Year-End 2021 Financial Results on Feb. 16, 2022 PR Newswire DUBLIN , Feb. 2, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT )...
--News Direct-- Schizophrenia is a complex brain disorder that can significantly impact patients. Fortunately, there are treatment options that may help. Learn more about the signs, symptoms, and treatments from National Institute of Mental Health (NIMH) . About A...
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium PR Newswire DUBLIN , Jan. 18, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to ne...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...